PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29440177-4	2018	Ponatinib was tested for efficacy in two patient-derived xenograft (PDX) models and one cell-line xenograft model of SCCOHT.Results: The receptor tyrosine kinase (RTK) family was enriched in siRNA screen hits, with FGFRs and PDGFRs being overlapping hits between drug and siRNA screens.	ponatinib	0-9	ret proto-oncogene	Homo sapiens	137-161	
29440177-4	2018	Ponatinib was tested for efficacy in two patient-derived xenograft (PDX) models and one cell-line xenograft model of SCCOHT.Results: The receptor tyrosine kinase (RTK) family was enriched in siRNA screen hits, with FGFRs and PDGFRs being overlapping hits between drug and siRNA screens.	ponatinib	0-9	ret proto-oncogene	Homo sapiens	163-166	
29440177-6	2018	We further identified ponatinib as the most effective clinically approved RTK inhibitor.	ponatinib	22-31	ret proto-oncogene	Homo sapiens	74-77